ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01672606
Recruitment Status : Completed
First Posted : August 27, 2012
Last Update Posted : February 29, 2016
Sponsor:
Information provided by (Responsible Party):
Malin Jonsson Fagerlund, Karolinska University Hospital

Brief Summary:
This study describe the effect of partial neuromuscular blockade of rocuronium on the acute hypoxic ventilatory response in patients with OSA before and after 3 month of CPAP treatment.

Condition or disease Intervention/treatment Phase
OSA Rocuronium Neuromuscular Blockade Hypoxic Ventilatory Response CPAP Drug: Rocuronium Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Effect of Partial Neuromuscular Blockade by Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea-before and After Three Month CPAP Treatment. A Non-randomized, Non-blinded Study.
Study Start Date : May 2012
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Rocuronium
Intravenous infusion of rocuronium with the goal of TOF 0.70 and >0.90
Drug: Rocuronium
Partial neuromuscular blockade with rocuronium with a TOF 0.70
Other Name: CPAP




Primary Outcome Measures :
  1. Hypoxic ventilatory response [ Time Frame: At baseline, with CPAP, at TOF 0.70 and at TOF >0.90. At diagnosis and after 3 month of CPAP treatment at home ]

Secondary Outcome Measures :
  1. Hypercarbic ventilatory response [ Time Frame: At baseline, with CPAP, at TOF 0.70 and at TOF >0.90. At diagnosis and after 3 month of CPAP treatment at home ]
  2. Hypoxic ventilatory response [ Time Frame: At diagnosis and after 3 month of CPAP treatment at home ]
  3. Hypoxic ventilatory response during acute CPAP treatment [ Time Frame: At diagnosis and after 3 month of CPAP treatment ]
  4. Hypercarbic ventilatory response [ Time Frame: At diagnosis and after 3 month of CPAP treatment at home ]
  5. Hypercarbic ventilatory response during acute CPAP treatment [ Time Frame: At diagnosis and after 3 month CPAP treatment at home ]
  6. Upper airway obstruction [ Time Frame: At TOF 0.70 and TOF >0.90. At diagnosis and after 3 month CPAP treatment. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male with diagnosed moderate OSA (AHI 15-30), untreated, but planned for CPAP treatment. Healthy except for OSA and well controlled tablet treated hypertension where the treatment has not been changed during the last 3 month. None smokers. 18-70 years old. BMI <35.

Exclusion Criteria:

  • If they don´t fit the inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01672606


Locations
Sweden
Department of Anesthesiology, Surgical Sciences and Intensive Care Medicine, Karolinska University Hospital
Stockholm, Sweden, se-17176
Sponsors and Collaborators
Malin Jonsson Fagerlund
Investigators
Principal Investigator: Malin Jonsson Fagerlund, MD, PhD Karolinska University Hospital and Karolinska Institutet

Responsible Party: Malin Jonsson Fagerlund, MD, PhD, Karolinska University Hospital
ClinicalTrials.gov Identifier: NCT01672606     History of Changes
Other Study ID Numbers: OSA ROC
First Posted: August 27, 2012    Key Record Dates
Last Update Posted: February 29, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Sleep Apnea, Obstructive
Hypoxia
Sleep Apnea Syndromes
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Rocuronium
Neuromuscular Nondepolarizing Agents
Neuromuscular Blocking Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs